Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study
Vedolizumab and ustekinumab appear to be effective in inducing and maintaining CFR in pediatric-onset IBD. Randomized controlled trials are needed to confirm these results.
Authors
- A. Vanrenterghem
- D. Djeddi (ORCID: https://orcid.org/0000-0002-9513-0275)
- Edouard Lacotte
- Delphine Ley (ORCID: https://orcid.org/0000-0002-7280-7861)
- Selma Rebus (ORCID: https://orcid.org/0009-0000-0266-1062)
- Stéphanie Coopman (ORCID: https://orcid.org/0000-0003-0083-7241)
- Claire Dupont (ORCID: https://orcid.org/0000-0002-7355-6515)
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Lille’s Cardiology Hospital (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Lille Inflammation Research International Center (FR)
- Délégation Normandie (FR)
- Institute for Translational Research in Inflammation (FR)
- Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau
- Université de Rouen Normandie (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1002/jpn3.12384
- Citations
- 5
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.75